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Background: Women with thalassaemia major typically experience hypogonadotropic hypogonadism
because of the toxic effects of iron overload on the anterior pituitary. Moreover, in affected women, serum
anti-Mullerian hormone (AMH) and antral follicle count (AFC) are also shown to be reduced, suggesting
that the peripheral excess of iron could also harm the ovarian reserve. To date, the detrimental effects of
the disease on oocyte quality have not been investigated.
Materials and methods: Women with thalassaemia major who underwent in vitro fertilization (IVF) cycles
were retrospectively identified over a 9 years period. They were matched (with a 1:5 ratio) by study
period and age to a control group of infertile women undergoing IVF. Embriological variables were
compared between the two groups. The primary outcome was the rate of top quality embryos.
Results: Twenty-one women with thalassaemia major (exposed group) and 105 controls (unexposed
group) were ultimately included. Serum AMH was 0.6 [0.2–1.8] and 1.5 [0.7–3.5] ng/ml, respectively
(p = 0.05). AFC was 4 (1–7.5) and 11 (5.5–16), respectively (p < 0.001). The total dose of gonadotropins
used was higher in exposed women but the number of retrieved oocytes and oocytes used did not differ.
The fertilization rate was higher in exposed compared to unexposed women, being 100% (76–100%) and
75% (50–100%). respectively (p = 0.03). The cleavage rate was also higher, being 75% (39–100%) and 50%
(29–64%), respectively (p = 0.04). In contrast, the rate of top quality embryos did not differ, being 20%
(0–76%) and 25% (5–50%), respectively (p = 0.98).
Conclusions: Despite lower ovarian reserve, oocyte quality is not significantly affected in women with
thalassaemia major.
© 2019 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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Thalassaemia is one of the most common monogenic disease
worldwide and still poses a serious health problem [1]. From a
molecular point of view, it is characterized by the partial or
complete deficiency in the synthesis of α or β-globin chains that
compose the major adult hemoglobin (α 2 β 2). As a consequence,
impaired globin chains precipitate in the cell, causing premature
destruction of both red blood cells precursors and mature red
blood cells [2]. From a therapeutic point of view, when globin
chains deficiency is complete (thalassaemia major, TM), patients
require lifelong regular blood transfusions that result in iron* Corresponding author at: Infertility Unit, Fondazione Ca’ Granda, Ospedale
Maggiore Policlinico, Via M. Fanti, 6, 20122, Milan, Italy.
E-mail address: laura.mensi1@gmail.com (L. Mensi).
http://dx.doi.org/10.1016/j.eurox.2019.100048
2590-1613/© 2019 The Authors. Published by Elsevier B.V. This is an open access article unoverload-related complications such as liver insufficiency, cardio-
myopathy and endocrine dysfunction [2].
Progress in the therapeutic approach, including the availability
of oral iron chelators, has led to improved patient survival and
quality of life [2]. Consequently, among female patients, parent-
hood has become possible and the desire for pregnancy has grown
[3–6]. However, reproductive disorders are still common: iron
overload produces a toxic effect on the anterior pituitary, leading to
hypogonadotropic hypogonadism, with low gonadotropin secre-
tion, amenorrhea and infertility [3]. In addition, affected women
face pregnancy complications such as intrauterine growth
restriction, low birth weight and prematurity [6].
Recent studies also revealed that patients with TM have
lower levels of anti-Mullerian hormone (AMH) and reduced
antral follicular count (AFC), suggesting that the peripheral
excess of iron may also be toxic locally to the gonads, harming
the ovarian reserve [4,7–11]. In addition, iron excess, in particularder the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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impact on oocyte quality. Increased levels of redox activity in
follicular fluid of women with the disease and an inverse
correlation between serum AMH and non-transferrin-bound iron
levels have been reported [12]. To note, free iron can generate
reactive oxygen species (ROS) through the Fenton reaction, causing
oxidative stress, a condition that was shown to negatively affect
oocyte developmental competence [10]. However, this potential
detrimental effect remains speculative since direct evidence on
oocyte quality in women with TM is lacking.
Disentangling whether oocyte quality is hampered in women
with TM is a relevant clinical issue. Ovulation induction with
exogenous gonadotropins can indeed compensate for the central
endocrine disruption but cannot overcome the detrimental effects
on the quality of the oocytes. In fact, if a specific and time-related
injury to oocyte quality is demonstrated, one may claim oocyte
preservation at a young age in affected women. In order to shed
light on this topic, we retrospectively collected data on oocyte
competence from women with TM who underwent in vitro
fertilization (IVF) cycles and compared them to a control group
of age-matched infertile women.
Materials and methods
Women with TM who were referred to the Infertility Unit of the
Fondazione Ca’ Granda, Ospedale Maggiore Policlinico of Milan,
Italy between January 2009 and December 2017 were retrospec-
tively identified (exposed group). We included women aged 18–42
years who underwent at least one IVF or intracytoplasmatic sperm
injection (ICSI) cycle. Women exclusively performing ovarian
hyperstimulation were excluded. Controls (unexposed group)
were infertile women undergoing IVF-ICSI matched to cases in a
5:1 ratio by age (6 months) and study period (the following five
women fulfilling the criteria for selection and matching).
Additional exclusion criteria for both groups were as follows: 1)
previous IVF-ICSI cycles, 2) previous ovarian surgery, 3) severe
male factor of infertility requiring surgical sperm extraction.
Women with abnormal uterine cavity (submucosal fibroids,
endometrial polyps, uterine septum), hydrosalpinx and dysthyr-
oidism could be included after surgical or medical correction. Both
exposed and unexposed women were included only for the first
treatment cycle reaching oocyte retrieval. In our Unit women with
FSH  30 IU/L were excluded. The study was approved by the local
institutional review board. An informed consent was not required
since this is a retrospective study. However, all women referring to
our unit signed an informed consent for their data to be used for
scientific purposes.
Women with TM referred to our unit for infertility were
managed according to a standardized protocol. Firstly, they
underwent a pre-pregnancy clinical assessment as reported in
details elsewhere [6]. Then, they underwent a diagnostic fertility
work-up including transvaginal ultrasound, serum hormonal
evaluation (AMH, TSH, prolactin, FSH, LH and estradiol) and tubal
patency assessment. The male partner provided two semen
samples at least two months apart for fertility evaluation according
to WHO criteria [13,14]. Women with an unremarkable work-up
were advised to undergo ovulation induction. Otherwise, they
were advised to IVF or ICSI. IVF was also considered after six failed
cycles of ovulation induction. Given the long-lasting overwhelm-
ing therapeutic burden suffered by affected women, an individu-
alized and patient-centred approach was applied and, if requested
by the patient, the number of ovulation induction cycles prior to
shift to IVF could be reduced. All women were managed by a single
physician (R.B.).
Ovarian hyper-stimulation was performed as reported in details
elsewhere [15,16]. Briefly, three different protocols could bechosen for unexposed women, i.e. the long protocol, the protocol
with Gonadotropin Releasing Hormone (GnRH) antagonists and
the flare-up protocols. On the contrary, women with TM were not
treated with GnRH analogues, giving the documented hypogona-
dotropic state. Dosages of FSH administered varied between 100
and 450 IU daily and could be modified during treatment. Women
with TM systematically received also LH in a 1:2 ratio compared to
FSH. Ovarian hyper-stimulation cycles monitoring included serial
transvaginal ultrasounds and peripheral assessments of oestro-
gens and progesterone concentrations. Ovulation trigger was
performed when 3 follicles with a mean diameter 17 mm were
observed. Oocyte retrieval was performed 36 h later. ICSI and IVF
were performed in a standard way [15]. Embryos were systemati-
cally evaluated at day 2 or 3 and classified according to
standardized embryological criteria [17]. Information on embryo
quality at cleavage stage was thus always available. Embryo
transfer could be done at cleavage stage or blastocyst stage.
Supernumerary embryos or, in some cases (retrieval of more than
15 oocytes or progesterone >1.5 ng/ml on the day of ovulation
trigger), all available embryos were frozen and transferred in a
subsequent cycle.
We chose the rate of top quality embryos as the primary
outcome. Secondary outcomes were number of follicles 11 mm at
the end of the stimulation, number of oocytes retrieved, number of
suitable oocytes, number and quality of the embryos, fertilization
rate, cleavage rate, clinical pregnancy (defined as the US detection
of an intrauterine gestational sac and a viable embryo) and live
birth rate. Data was analyzed using the SPSS software 18.0
(Chicago, IL). Fisher Exact test, Student t-test, unpaired Wilcoxon
non parametric test and Spearman correlation were used as
appropriate. P values  0.05 were considered statistically signifi-
cant. The power of the study was calculated setting type I error at
0.05 and expecting the presence of at least one top quality embryo
in 80% of cases in unexposed women. The number of women with
TM identified in our study (n = 21) consented us to detect as
statistically different a drop in the rate of top quality embryos
below 50% with a statistical power of 80%.
Results
Thirty-five women with TM referred to our Unit for infertility
during the study period. Fourteen (40%) received only ovarian
stimulation, of whom six (43%) achieved a live birth. The remaining
twenty-one (60%) underwent at least one IVF cycle and were
included in the study. All were diagnosed with β-TM, except one
case of β-thalassaemia intermedia. This latter patient was included
because, from a clinical point of view, she was managed as a TM
case. Twelve of them (57%) shifted to IVF after failure of ovarian
stimulation cycles, while nine (43%) received IVF straight (in five
cases no other concomitant factors of infertility were present).
Serum ferritin of the 21 included women was 1032  828 ng/dl
and the duration of transfusional therapy was 33.5  4.1 years.
Eighteen women (86%) had concomitant HCV infection and two
(10%) had type I diabetes. Primary and secondary amenorrhea was
diagnosed in 17 (81%) and 4 (19%) women, respectively.
These 21 exposed women were matched to 105 unexposed
controls. Baseline clinical characteristics of the two study groups
are shown in Table 1. Affected women had lower serum AMH and
AFC. In four of them (19%), a concomitant male cause of infertility
was diagnosed.
In women with TM, the total dose of FSH and LH used was
4400  1573 and 2200  786 IU, respectively. Controls were
scheduled to a long protocol, a protocol with GnRH-antagonist
and a flare-up protocol in 27 (26%), 58 (55%) and 20 (19%) subjects,
respectively. The total dose of gonadotropins used was
2428  1225 IU (p < 0.001 compared to exposed women). Duration
Table 1
Baseline clinical characteristics of the study groups.
Characteristics Thalassemia Controls p
n = 21 n = 105
Age (years) 35.1  2.7 35.1  2.6 0.99
BMI (kg/m2) 23.1  3.5 22.1  4.7 0.36
Previous deliveries 2 (10%) 5 (5%) 0.33
AMH (ng/ml) 0.6 [0.2–1.8] 1.5 [0.7–3.5] 0.05
AFC 4 [1–7.5] 11 [5.5–16] <0.001
Indication to IVF <0.001
Unexplained 0 (0%) 32 (31%)
Endometriosis 0 (0%) 22 (21%)
Tubal factor 0 (0%) 12 (11%)
Anovulation 17 (81%) 3 (3%)
Male factor 0 (0%) 21 (20%)
Mixed 4 (19%) 15 (14%)
AFC: Antral Follicle Count.
Data are repoorted as mean  SD or medain [interquartile range) or number
(percentage).
Table 3
Oocytes quality in exposed and unexposed women.
Outcome Thalassemia Unaffected p
n = 20 n = 102
Fertilization rate 100% (76–100%) 75% (50–100%) 0.03
Cleavage rate 75% (39–100%) 50% (29–64%) 0.04
Rate of top quality embryos 20% (0–76%) 25% (5–50%) 0.98
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12.3  2.1 and 9.4  2.3, respectively (p < 0.001). The other main
characteristics of the IVF cycles are presented in Table 2. No
statistically significant differences emerged.
Data on the quality of oocytes are presented in Table 3.
Fertilization rate and cleavage rate were higher in women with TM.
In contrast, the rate of top quality embryos did not differ. Finally,
we correlated serum ferritin and the duration of transfusional
therapy with oocyte quality outcomes. The correlation indexes
between ferritin and fertilization rate, cleavage rate and the rate of
top quality embryos was +0.15 (p = 0.53), +0.15 (p = 0.54) and 0.12
(p = 0.61), respectively. For the duration of transfusional therapy,Table 2
Characteristics of the IVF cycle.
Characteristics Thalassemia Unaffected p
n = 21 n = 105
Total number of follicles  11 mm 9.5  7.2 11.0  7.2 0.39
N. of oocytes retrieved 6.0  6.2 8.4  6.5 0.12
N. suitable oocytesa 5.5  6.0 6.1  4.7 0.60
N. of women with no suitable oocytes 1 (5%) 3 (3%) 0.52
Techniqueb 0.79
Classical IVF 5 (25%) 31 (30%)
ICSI 15 (75%) 71 (70%)
N. cleavage embryosb 2 [1–5] 3 [1–5] 0.51
No viable cleavage embryosb 1 (5%) 5 (5%) 1.00
N. top quality embryosb 1 [0–4.75] 2 [1–4] 0.72
No top quality embryosb 12 (60%) 78 (77%) 0.16
Embryo transferc 0.55
Cleavage stage 14 (74%) 76 (80%)
Blastocyst stage 5 (26%) 19 (20%)
Total N. of transfersc 0.83
1 13 (68%) 71 (75%)
2 4 (21%) 15 (16%)
3 2 (11%) 9 (9%)
Clinical pregnancyd 7 (33%) 37 (35%) 1.00
Live birthd 4 (19%) 34 (32%) 0.30
Data are repoorted as mean  SD or medain [interquartile range] or number
(percentage).
“Suitable oocytes’’ include metaphase II oocytes and type 1 cumulus-oocyte
complex according to the European Society for Human Reproduction and
Embryology Istanbul Consensus Conference, 2011.
Top quality embryo was defined as 4-cells embryo on day 2 or 8-cells embryo on day
3, with a relative degree of fragmentation 10%.
All clinical pregnancies were singletons.
a Suitable oocytes refer to metaphase II oocytes and type 1 cumulus-oocyte
complex according to the European Society for Human Reproduction and
Embryology Istanbul Consensus Conference, 2011.
b Data refer to subjects retrieving at least one suitable oocyte (n = 20 and 102 for
exposed and unexposed women, respectively).
c Data refer to patients performing embryo transfer (95 controls and 19 cases).
d Data include both pregnancies obtained with fresh and frozen embryo transfers.they were +0.18 (p = 0.44), +0.12 (p = 0.69) and +0.03 (p = 0.86),
respectively.
Discussion
In this study, we did not observe an impairment of oocyte
quality in women with TM undergoing IVF. The rate of top quality
embryos (our primary outcome) was actually not altered in
affected women. Evidence emerging from the secondary outcomes
also supports our conclusion since none of the analyzed
embryological variables was significantly impaired. Moreover,
when we investigated the potential time-related injury of iron
overload on oocyte function, we found no correlation between
serum ferritin or duration of transfusional therapy and oocyte
quality outcomes. The absence of any gradient effect actually
confirms the lack of harmful effects of the disease on oocyte
quality. To our knowledge, this is the first study reporting on the
quality of the oocytes of women with TM.
A surprising result of our study is the observation of a
paradoxical improved fertilization rate and cleavage rate in
women with TM. This unexpected observation is difficult to
explain and a type I error is the most plausible explanation.
However, we cannot exclude a different and counter-intuitive
explanation, i.e. a biological reaction to a somehow partly
unfavourable environment. Of interest here is that exposure of
oocytes to a sublethal stress was shown to be paradoxically
beneficial in some situations, at least in the earlier phases of
embryo development in animal models [18,19]. To note, we
observed a similar effect in human oocytes accidentally exposed to
the content of ovarian endometriomas [20], rich in free iron
content [21]. However, it has to be recognized that this intriguing
interpretation is highly speculative and more evidence is needed.
Previous studies on ovarian function and TM mainly focused on
ovarian reserve and generally supported an impairment: AMH and
AFC are consistently lower [4,7–11]. Our data is in agreement with
these findings since both biomarkers resulted reduced in exposed
women. In this regard, the observation that in our study the
number of oocytes retrieved was similar in exposed and
unexposed women is not in disagreement and cannot be used
to question the detrimental effects on ovarian reserve since the
total dose of gonadotropins administered in the two groups
radically differed. To note, an histologic study in female
thalassaemic adolescents documented reduced number of
primordial follicles [22].
Overall, one may conclude from our findings and from the
available literature that women with TM could be exposed to an
accelerated depletion of the ovarian reserve but not to a
significant insult to oocyte quality. On one hand, this informa-
tion is reassuring since oocyte quality is more important than
the residual ovarian reserve on the chances of natural pregnancy
[23,24]. On the other hand, one might speculate that a complete
exhaustion of the ovarian reserve may occur prematurely, thus
potentially reducing the duration of the reproductive period and
causing childlessness in some women. Unfortunately, data on
the rate of premature ovarian insufficiency (POI) in women with
TM is lacking in the literature and this possible concern remains
speculative.
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underwent a complete program of ovulation induction without
IVF: this low adherence to the first line approach may be explained
by the long-lasting overwhelming therapeutic burden suffered by
these women and their comprehensible preference for more
effective treatments (even if more invasive). In our opinion, this
clinical observation deserves attention within the debate on the
possible role of fertility preservation in affected women. If the
majority of women with TM will ultimately undergo IVF, collecting
and storing oocytes at young age may actually increase the chances
of pregnancy. This consideration remains, however, theoretical.
Confirmation of a high rate of IVF use from other independent units
and in-depth cost-effectiveness analyses are warranted. To note,
previous experiences in different historical periods reported lower
rate of IVF use [25]. Finally, it is worth noting that the clinical
scenario of TM-related reproduction impairment may change in
the next future. New intensive and more effective chelation
therapies may reverse some endocrine complications as a result of
reduction in total body iron overload: a case of reversal of
hypogonadotropic hypogonadism with spontaneous pregnancy
has actually been reported in the literature [26].
Some limitations of our study should be acknowledged. Firstly,
the study is retrospective and includes a relatively small number of
participants. The former limitation is presumably of scant
relevance considering that we focused on validated and common
outcomes that are routinely recorded. A prospective recruitment
would take several years and cannot be expected to markedly
improve the quality of the information. Conversely, the small
sample size is a significant limitation (albeit inevitable given the
rarity of the condition). Of particular relevance here is the
unreliability of the data of pregnancy rate, the most valid mean
to measure oocyte quality: our study was underpowered for
meaningful conclusions on this outcome. Secondly, affected
women with POI could not be included, thus exposing our findings
to a possible selection bias. In this regard, however, it has to be
reminded that our aim was to provide evidence on the quality of
oocytes, not on the amount of ovarian reserve. Thirdly, one may
also argue that the inclusion of some women with endometriosis in
the unexposed group could have diluted the differences because of
the possible detrimental effect of iron also in this condition [21,27].
To rule out the effect of this possible confounder, all the analyses
were repeated excluding women with endometriosis (n = 22) but
results were mainly similar (data not shown).
In conclusion, oocyte quality does not seem to be affected in
women with TM. However, more comprehensive evidence and
additional contributions from independent groups are needed
for more robust conclusions on the possible role of fertility
preservation in women with TM.
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